{"id":"W3029297598","doi":"10.1200/jco.2020.38.15_suppl.tps6591","title":"INDUCE-3: A randomized, double-blind study of GSK3359609 (GSK609), an inducible T-cell co-stimulatory (ICOS) agonist antibody, plus pembrolizumab (PE) versus placebo (PL) plus PE for first-line treatment of PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Tolerability; Internal medicine; Clinical endpoint; Population; Antibody; Phases of clinical research; Oncology; Immunotherapy; Immunology; Clinical trial; Adverse effect; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002468369,0.002671284,0.003372534,0.0006748703,0.0006635772,0.001494531,0.001604316,0.002857639,0.009861805],"category_scores_gemma":[0.00198248,0.001046394,0.002003321,0.0005538147,0.001945439,0.001647248,0.0007046668,0.004353711,0.002084092],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009750303,"about_ca_system_score_gemma":0.001851606,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001065307,"about_ca_topic_score_gemma":0.002638967,"domain_scores_codex":[0.9990946,0.0004153111,0.00006325172,0.0001853801,0.00007536606,0.0001660551],"domain_scores_gemma":[0.998604,0.0003701011,0.0003132267,0.0001729327,0.00009389186,0.0004458088],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9768146,0.01484403,0.0001371171,0.0002655487,0.0003337662,0.00001629192,0.00002199368,0.0001621249,0.002253095,0.0001097576,0.000483596,0.004558219],"study_design_scores_gemma":[0.9390681,0.05939143,0.0003621945,0.00001258579,0.0001625254,0.00001095823,0.000009497327,0.0002504069,0.0002937355,0.0001275211,0.0002985977,0.00001242027],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9658776,0.002821184,0.001567809,0.001011631,0.002035295,0.01925116,0.002907002,0.0004274976,0.004100935],"genre_scores_gemma":[0.9496821,0.002030722,0.004783633,0.00251825,0.001306188,0.02883993,0.002078239,0.0001077311,0.008653317],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009861805,"threshold_uncertainty_score":0.03299099,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2139246181306748,"score_gpt":0.4678649286594228,"score_spread":0.253940310528748,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}